文献速递肿瘤 PET/CT核素与放射性配体治疗

基于PET/CT的影像基因组学支持KEAP1/NFE2L2通路靶向用于接受根治性放疗的非小细胞肺癌

PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy.
PubMed 文献 · J Nucl Med · 2024-02-15

基于770例公共队列构建RNA模型预测KEAP1/NFE2L2突变状态,再用PET/CT影像组学特征构建PET/CT模型预测RNA模型二分类输出,并在151例接受根治性容积调强弧形放疗的外部队列验证。PET/CT模型在测试队列中C统计量为0.7,并以风险比2.61(P=0.02)对局部复发风险实现显著分层。

要点

  • RNA模型在测试队列中C统计量为0.82。
  • PET/CT模型在训练队列101例中曲线下面积为0.90(P<0.001)。
  • 外部放疗队列中PET/CT模型以风险比2.61(P=0.02)显著分层局部复发风险。

核心结论

  • 该方法可利用PET/CT提取的影像组学特征预测KEAP1/NFE2L2突变状态,并在外部放疗队列中有效分类局部复发风险患者。

研究设计与样本

  • 基于770例公共队列,先以连续基因表达水平构建RNA模型预测KEAP1/NFE2L2突变状态并输出二分类结果。
  • 再以PET/CT提取的影像组学特征构建PET/CT模型预测RNA模型的二分类输出。
  • PET/CT模型在151例接受根治性容积调强弧形放疗的外部队列中验证。
  • 各模型均采用多层感知机网络方法构建、内部验证并在独立队列评估。

主要发现

  • RNA模型在测试队列中C统计量为0.82。
  • PET/CT模型在训练队列101例中曲线下面积为0.90(P<0.001)。
  • 在测试队列应用20%概率阈值时,PET/CT模型C统计量为0.7。
  • 同一影像组学模型在容积调强弧形放疗队列中按局部复发风险显著分层,风险比为2.61(P=0.02)。

关键数值与推荐

  • RNA模型在测试队列中C统计量为0.82。
  • PET/CT模型在训练队列101例中曲线下面积为0.90(P<0.001)。
  • 在测试队列应用20%概率阈值时,PET/CT模型C统计量为0.7。
  • 容积调强弧形放疗队列中局部复发风险分层的风险比为2.61(P=0.02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In lung cancer patients, radiotherapy is associated with a increased risk of local relapse (LR) when compared with surgery but with a preferable toxicity profile. The KEAP1/NFE2L2 mutational status (MutKEAP1/NFE2L2) is significantly correlated with LR in patients treated with radiotherapy but is rarely available. Prediction of MutKEAP1/NFE2L2 with noninvasive modalities could help to further personalize each therapeutic strategy. Methods: Based on a public cohort of 770 patients, model RNA (M-RNA) was first developed using continuous gene expression levels to predict MutKEAP1/NFE2L2, resulting in a binary output. The model PET/CT (M-PET/CT) was then built to predict M-RNA binary output using PET/CT-extracted radiomics features. M-PET/CT was validated on an external cohort of 151 patients treated with curative volumetric modulated arc radiotherapy. Each model was built, internally validated, and evaluated on a separate cohort using a multilayer perceptron network approach. Results: The M-RNA resulted in a C statistic of 0.82 in the testing cohort. With a training cohort of 101 patients, the retained M-PET/CT resulted in an area under the curve of 0.90 (P < 0.001). With a probability threshold of 20% applied to the testing cohort, M-PET/CT achieved a C statistic of 0.7. The same radiomics model was validated on the volumetric modulated arc radiotherapy cohort as patients were significantly stratified on the basis of their risk of LR with a hazard ratio of 2.61 (P = 0.02). Conclusion: Our approach enables the prediction of MutKEAP1/NFE2L2 using PET/CT-extracted radiomics features and efficiently classifies patients at risk of LR in an external cohort treated with radiotherapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Bourbonne V, Morjani M, Pradier O, et al. PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non-Small Cell Lung Cancer Treated with Curative Radiotherapy. J Nucl Med. 2024. PMID: 38360055. doi:10.2967/jnumed.123.266749

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。